Melanoma researchers shine at the State's premier cancer awards ceremony

Melanoma researchers shine at the State's premier cancer awards ceremony

3 November 2017

Melanoma Institute Australia’s world-leading researchers have excelled at the 2017 Cancer Institute NSW’s Premier Awards for Outstanding Cancer Research.

Hosted by the Cancer Institute NSW, the Awards honour the achievements of individuals and teams working across the cancer research sector to lessen the impact of cancer on the people of NSW.

Leading researchers from MIA have been acknowledged with three prestigious awards for their excellence in melanoma research which is changing clinical practice and saving lives.  

MIA’s Conjoint Medical Directors, Professor Richard Scolyer and Professor Georgina Long, and their research team received the award for Excellence in Translational Cancer Research. The award recognises contributions having a lasting impact and demonstrating sustained progress against cancer.

The team has made key discoveries and transformed global melanoma patient care. Their discoveries range from defining new determinants of risk in primary melanoma which have impacted international reporting guidelines; development of diagnostic tests that have become clinical practice worldwide; identifying novel molecular phenotypes of melanoma; and leading development of novel treatments particularly in patients with advanced melanoma where there were no effective therapies previously.

Professor Richard Kefford AM has been named Outstanding Cancer Researcher of the Year. This prestigious award is given to an individual who has made an outstanding and sustained contribution to cancer research and has a record of substantive and noteworthy publications.

Professor Kefford’s research has played a seminal role in revealing the genetics of melanoma and he has authored more than 300 journal publications, chapters and books. He has been a Principal Investigator on more than 40 clinical trials exploring new immunotherapies that are transforming the treatment of melanoma. In addition, he has mentored a new generation of leading laboratory and clinical researchers in the field of cancer.

Professor Helen Rizos and the Melanoma Translational Research Team have won the Wildfire Highly Cited Publication Award. The award is given to researchers for a highly cited publication that is expected to significantly influence cancer control or further research. The publication that won Professor Rizos and the MIA team the award was published in Clinical Cancer Research and determined that first line combination therapies that target multiple pathways may have more success than an adaptive sequential approach. This publication has led to a new standard of care for patients with BRAF-mutant advanced melanoma being treated with combination BRAF and MEK inhibitors.

“We are extremely proud of our award winners but also our wide network of MIA-affiliated research teams,” said MIA’s CEO Carole Renouf. “The goal we all share is zero deaths from melanoma and we are making rapid progress towards cure.”

MIA’s Conjoint Medical Director Professor Richard Scolyer said, “The depth and breadth of research undertaken at MIA ensures that we are key players on the world stage of melanoma research. It is an honour to lead this organisation and I am delighted that our people are being recognised for their tremendous efforts.”

MIA’s Conjoint Medical Director Professor Georgina Long added, “The passionate people at MIA work tirelessly to consistently produce research that has a direct positive impact on the lives of patients and their families.”

Chief Cancer Officer and CEO of the Cancer Institute NSW, Professor David Currow said, “Ten years ago, people diagnosed with advanced melanoma had their life expectancy measured in months. Now, Australian people with melanoma have a range of increasingly personalised treatment options. This has seen response rates improve from less than 10 per cent with older chemotherapy to between 40 and 70 per cent today.

“I commend these researchers for their tireless efforts and congratulate them on their tremendous success in changing the way we treat these cancers.”

The awards ceremony was held on Friday 3rd November at the Four Seasons Hotel Sydney. Adam Spencer, as the Master of Ceremonies, joined more than 300 pre-eminent guests from the health and medical research sector to share successes and forge collaborations.

5 Minutes with Dr Scot Ebbinghaus
05 May 2016

5 Minutes with Dr Scot Ebbinghaus

Dr Scot Ebbinghaus chats to us about an exciting clinical trial at MIA and where melanoma treatment is headed in the future.

Opdivo available on PBS for advanced melanoma patients
01 May 2016

Opdivo available on PBS for advanced melanoma patients

A new melanoma treatment has been listed on the PBS today, giving another option for advanced melanoma patients. 

5 Minutes with Dr Louise Jackett
27 Apr 2016

5 Minutes with Dr Louise Jackett

MIA's Pathology Fellow Dr Louise Jackett tells us why she's joined our fellowship program to learn from the best.

MIA patient's plight highlighted in ABC series
27 Apr 2016

MIA patient's plight highlighted in ABC series

MIA doctors and patient have featured in the final episode of ABC’s ground-breaking series Keeping Australia Alive.

Recruiting: Pregnancy and moles study
26 Apr 2016

Recruiting: Pregnancy and moles study

Specialist dermatologists at MIA are researching moles during pregnancy and we are looking for study recruits.

The role of radiotherapy in melanoma
22 Apr 2016

The role of radiotherapy in melanoma

New research is re-writing the textbooks on what we know about melanoma by highlighting the effectiveness of radiotherapy as a treatment, reversing a long-held belief that melanoma was resistant to radiotherapy.

Australian melanoma rates take the silver – and that's good news
31 Mar 2016

Australian melanoma rates take the silver – and that's good news

However, Australia's burden of melanoma will stay very high over the next 15 years unless we do more. MIA's Professor Graham Mann explains.

Australia unites taking small steps to make a big difference for melanoma research
23 Mar 2016

Australia unites taking small steps to make a big difference for melanoma research

Thank you to everyone involved in making Melanoma March 2016 a huge success

And they're off... Melanoma March 2016 begins!
29 Feb 2016

And they're off... Melanoma March 2016 begins!

Melanoma March 2016 has officially begun with more than 300 people marching in Rockingham and Devonport.

5 Minutes with Carole Renouf
29 Feb 2016

5 Minutes with Carole Renouf

MIA's new CEO Carole Renouf has been in her role only a month, but is already making plans for the future of MIA.

Opinion: Outing Melanoma
24 Feb 2016

Opinion: Outing Melanoma

In the wake of Susie Maroney's recent announcement that she is battling melanoma, CEO Carole Renouf's opinion piece weighs in on the critical need we have in Australia to raise awareness about melanoma. 

Congratulations Professor Georgina Long
22 Feb 2016

Congratulations Professor Georgina Long

MIA's Georgina Long has been appointed Professor and awarded a coverted prize in medial research.

Melanoma March 2016: Where your funds are going
19 Feb 2016

Melanoma March 2016: Where your funds are going

Melanoma March 2016 funding will be used to initiate an ambitious new project that will support the best possible care for melanoma patients around Australia through a new data and communication platform. 

New research shows long-term survival in group of advanced melanoma patients treated with BRAF inhibitors
05 Feb 2016

New research shows long-term survival in group of advanced melanoma patients treated with BRAF inhibitors

New MIA-led research has been published in the Journal of Clinical Oncology.

Melanoma March 2016 is launched
02 Feb 2016

Melanoma March 2016 is launched

Melanoma March was officially launched today with the announcement of the national research project funded by the march. 

MIA's research pivotal in TGA's approval of new therapy
01 Feb 2016

MIA's research pivotal in TGA's approval of new therapy

Clinical research undertaken at MIA has been pivotal in supporting the recent Therapeutic Goods Administration approval of Opdivo (nivolumab) for advanced melanoma.

The Face of Melanoma March
28 Jan 2016

The Face of Melanoma March

Maddison, the face of our Melanoma March campaign, knows the far-reaching effects that melanoma can have.

Q&A With An Expert: Dermatologist
28 Jan 2016

Q&A With An Expert: Dermatologist

MIA's Dermatologist Associate Professor Pascale Guitera answers your most commonly-asked questions about sunscreen. 

New figures show melanoma most common cancer in young Queenslanders
08 Jan 2016

New figures show melanoma most common cancer in young Queenslanders

Statistics released by the Queensland Cancer Registry have revealed that melanoma is the most common cancer in young Queenslanders aged under 35, with rates in young women more than 20 per cent higher than in men.

5 minutes with Associate Professor Georgina Long
17 Dec 2015

5 minutes with Associate Professor Georgina Long

As 2015 draws to a close, we took the opportunity to speak with Associate Professor Georgina Long to discuss her crucial role at Melanoma Institute Australia, and the current research projects she is working on.